Biotecon plans to distribute SARS-CoV-2 test globally

2020 03 06 18 55 2739 Virus Coronavirus China2 400

Biotecon Diagnostics announced that it is planning for the distribution of its SARS-CoV-2 polymerase chain reaction (PCR) detection test worldwide.

The Potsdam, Germany-based company's Acu-Corona 2.0/3.0 test, which detects the virus from oral or nasal samples and provides results in 90 minutes, is approved for research purposes at this time. The test is awaiting receipt of the CE Mark in Europe, as well as an emergency use authorization from the U.S. Food and Drug Administration. Biotecon said in a statement that the product will be marketed in Europe and the U.S. through an exclusive distribution agreement with a company in Singapore.

Page 1 of 14
Next Page